The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures
about
Towards tumor immunodiagnosticsCheckpoint Inhibitors and Their Application in Breast CancerImmunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trialsInsight to drug delivery aspects for colorectal cancerRethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerCancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant StateTrial Watch: Adoptive cell transfer for oncological indicationsLymphangiogenic Markers and Their Impact on Nodal Metastasis and Survival in Non-Small Cell Lung Cancer--A Structured Review with Meta-AnalysisCurrent Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast CancerControl of CD8 T-Cell Infiltration into Tumors by Vasculature and MicroenvironmentDuality of the immune response in cancer: lessons learned from skinMechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissuesImmune escape mechanisms as a guide for cancer immunotherapyTowards the introduction of the 'Immunoscore' in the classification of malignant tumoursThe PD1:PD-L1/2 Pathway from Discovery to Clinical ImplementationImmunotherapy in human colorectal cancer: Challenges and prospectiveValidation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validationEpidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancerFrom mice to humans: developments in cancer immunoeditingLung Cancer Gene Signatures and Clinical PerspectivesImpact of carbon nanotubes and graphene on immune cellsHuman melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk.Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.Combining antibody-directed presentation of IL-15 and 4-1BBL in a trifunctional fusion protein for cancer immunotherapy.Intravital and whole-organ imaging reveals capture of melanoma-derived antigen by lymph node subcapsular macrophages leading to widespread deposition on follicular dendritic cells.B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancerDirect T cell-tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme.Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma.Precision medicine in breast cancer: reality or utopia?New insights into the role of EMT in tumor immune escape.Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing miceTargeting the PD-1 pathway: a promising future for the treatment of melanoma.CXCL17 expression predicts poor prognosis and correlates with adverse immune infiltration in hepatocellular carcinoma.Copy number loss of the interferon gene cluster in melanomas is linked to reduced T cell infiltrate and poor patient prognosisPrognostic value of preoperative absolute lymphocyte count in recurrent hepatocellular carcinoma following thermal ablation: a retrospective analysisA phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies.Meta-analysis and metagenes: CXCL-13-driven signature as a robust marker of intratumoral immune response and predictor of breast cancer chemotherapeutic outcome.How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies
P2860
Q26738691-772BA323-61B4-4162-86EC-274D641BA673Q26745442-28F84E2E-1177-47C0-8EA0-17126A37F815Q26765115-FB072882-64AA-4C52-BF7D-A46F9FA9229AQ26774682-0B5A38DF-006F-4556-97D4-3E076433B98FQ26780387-473AD1A9-D52A-4A46-BC87-B740E6A4D374Q26782573-0E29483D-3E69-4604-BEC2-736D28AF0572Q26785545-D3ADDB8B-17EE-43A6-B3A8-EBDFC3A90A02Q26797490-A199156F-7017-4C8B-9C2B-1CF18B71FE10Q26798074-D537B591-3DA2-47AF-81E6-DE5DD50873F8Q26799117-53384DC0-E42D-4EFA-B4CA-9882631B8DFFQ26999379-ECE3F17B-FEA4-47F4-B029-0BA80FA19F4EQ27003907-F9B0B32F-4FEB-4710-B07A-23C43F736FD7Q27024502-5D93DEB2-066A-4DFE-88F6-BCFE17BC3EB7Q27026489-3B22C9D2-6643-450B-B350-98A4338EC7D4Q28066941-9B97C348-9360-4DAE-BE87-B118F16DA7BEQ28068788-8A366C35-5F0B-4936-BEE9-4E007FB01AC0Q28075719-891675A7-E9CD-45AB-A51E-E08815A26484Q28084216-AB79D090-8538-4839-B994-C0B7EE99EA2CQ28088304-BCA1808D-A617-4F15-94C4-9A46FA0698BAQ28387769-6DFAC6C8-B4B6-46D3-A5EB-BFA39B6D7881Q28388540-A05781E5-DDB0-4878-9D06-04475D4F7D5FQ30274920-E8B33CD2-BBC2-499A-BCAF-7FB15940F8B7Q30276126-48BD7518-7F0B-4212-815E-97CF92B7E775Q30276128-663DFA0F-59F5-4698-B030-81A0E943ED16Q30580198-C191626B-64E7-4529-94E1-7FC954460434Q30627418-4813F2A6-9979-479C-BF59-7B487FB18B56Q33721433-D313B55B-7EA3-4DC5-B120-9CDFA0815E11Q33750137-97CA0009-B52F-4B85-9BE1-0197671D7BDEQ33798098-9BC89A88-131A-45E8-B67A-7612544682DDQ33809114-9BC7EA78-C439-45E6-B567-66A3EA218138Q33869781-EE337154-812E-4AAD-A330-80669B8B36A1Q33927165-393FCE1A-B358-4E74-B45E-83DF6CE20812Q33946513-3BF23732-8253-4098-8E2E-9693F19AAF4EQ34323663-BEFCF60A-9E69-476A-A60A-77A345CD1D34Q34338284-3F992BF5-427C-4E51-86DF-8F9798DC5B13Q34352741-AF0671A3-CAF6-4834-8375-B479068B36BBQ34353111-E19F1937-E9A4-4839-93D7-D3BB04C635DBQ34372945-E95D8960-6071-4A04-BE77-85DD7A20B036Q34418112-8553F39A-B4D1-4405-AAD7-57BACB06997DQ34511672-726A8686-9C5B-4BA6-A878-70BE88ED5E6E
P2860
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The continuum of cancer immuno ...... ve, and mechanistic signatures
@ast
The continuum of cancer immuno ...... ve, and mechanistic signatures
@en
The continuum of cancer immuno ...... ve, and mechanistic signatures
@nl
type
label
The continuum of cancer immuno ...... ve, and mechanistic signatures
@ast
The continuum of cancer immuno ...... ve, and mechanistic signatures
@en
The continuum of cancer immuno ...... ve, and mechanistic signatures
@nl
prefLabel
The continuum of cancer immuno ...... ve, and mechanistic signatures
@ast
The continuum of cancer immuno ...... ve, and mechanistic signatures
@en
The continuum of cancer immuno ...... ve, and mechanistic signatures
@nl
P3181
P1433
P1476
The continuum of cancer immuno ...... ve, and mechanistic signatures
@en
P2093
Francesco M. Marincola
Helen K. Angell
P3181
P356
10.1016/J.IMMUNI.2013.07.008
P407
P577
2013-07-25T00:00:00Z